Ozenoxacin

Base Information

• Chemical Name: Ozenoxacin
• CAS No.: 245765-41-7
• Molecular Formula: C21H21N3O3
• Molecular Weight: 363.41982
• UNII: V0LH498RFO
• DSSTox Substance ID: DTXSID00947446
• Nikkaji Number: J1.697.283E
• Wikipedia: Ozenoxacin
• Wikidata: Q17125399
• NCI Thesaurus Code: C90935
• RXCUI: 1994739
• Metabolomics Workbench ID: 153812
• ChEMBL ID: CHEMBL3990047
• Mol file: 245765-41-7.mol

Synonyms:1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;ozanex;ozenoxacin;xepi

Chemical Property of Ozenoxacin

Chemical Property:

• Boiling Point: 573.5±50.0 °C(Predicted)
• PKA: 6.46±0.50(Predicted)
• PSA: 87.45000
• Density: 1.372±0.06 g/cm3(Predicted)
• LogP: 3.17700
• Storage Temp.: 2-8°C(protect from light)
• Solubility.: DMSO (Slightly)
• XLogP3: 4.1
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 4
• Exact Mass: 363.15829154
• Heavy Atom Count: 27
• Complexity: 645

Purity/Quality:

99% ^*data from raw suppliers

Ozenoxacin,>90% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
• Recent ClinicalTrials: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
• Recent EU Clinical Trials: A phase III 2 arms, multicenter, randomised, double-blind study to assess the efficacy and safety of ozenoxacin 1% cream applied twice daily for 5 days versus placebo in the treatment of patients with impetigo
• Recent NIPH Clinical Trials: A Phase 3 study of M512102 with impetigo.
• Description: Ozenoxacin is used to treat impetigo (a skin infection caused by bacteria) in adults and children 2 months of age and older. Ozenoxacin is in a class of medications called antibacterials. It works by killing and stopping the growth of bacteria on the skin. To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older. Ozenoxacin is a novel, nonfluorinated quinolone antibiotic discovered by Toyama Chemical Co. Ltd. and developed by Maruho Co. Ltd. Ozenoxacin was approved by the PMDA of Japan in September 2015 for the treatment of acne and skin infections. Ozenoxacin shows potent antibacterial activity against anaerobic and aerobic, gram-positive and -negative bacteria, especially those implicated in superficial skin infections such as S. aureus, Staphylococcus epidermidis, and Propionibacterium acnes. The mechanism of action of ozenoxacin involves the drug’s affinity for DNA gyrase and DNA topoisomerase IV and upon binding triggers bacterial apoptosis.
• Uses: Ozenoxacin is a non-fluorinated topical quinolone. It exhibits antimicrobial activity against?propionibacteria and staphylococci. Ozenoxacin can be used to treat acne and superficial skin infections.

Technology Process of Ozenoxacin

There total 21 articles about Ozenoxacin which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 93.7%

C31H31N3O5 → ozenoxacin (245765-41-7)

Guidance literature:

With sodium hydroxide; at 20 - 120 ℃; for 5h;

Reference yield: 93.1%

C28H33N3O5 → ozenoxacin (245765-41-7)

Guidance literature:

C₂₈H₃₃N₃O₅; With trifluoroacetic acid; In dichloromethane; at 20 ℃; for 1h;

With water; sodium hydroxide; In ethanol; at 60 ℃; for 2h; Reagent/catalyst; Solvent; Temperature;

Reference yield: 91.5%

C30H29N3O4 (446299-90-7) → ozenoxacin (245765-41-7)

Guidance literature:

With sodium hydroxide; at 100 ℃; for 6h; Reagent/catalyst;

upstream raw materials:

ethyl 7-chloro-1-cyclopropyl-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate

C₃₀H₂₉N₃O₄

2,5-dibromo-3-methylpyridine

(5-bromo-6-methylpyridin-2-yl)methylamine

Refernces

• 1、 -. "CRYSTALLINE FORM OF OZENOXACIN AND PROCESSES FOR PREPARATION THEREOF". . . Retrieved 2020/05/12.
• 2、 -. "Quinolonecarboxylic acid derivatives or salts thereof". Page column 37. . Retrieved 2010/01/30.